Article

Single-Cell RNA-seq Reveals LGALS1 and LAG3 as Novel Drivers of Ibrutinib Resistance in Chronic Lymphocytic Leukemia

2021-08-31

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>Chronic lymphocytic leukemia (CLL) is a highly heterogeneous malignant lymphoproliferative B-cell disorder that can be treated using ibrutinib, a Bruton’s tyrosine kinase inhibitor. However, the ibrutinib resistance of CLL patients has caused widespread concerns, necessitating the development of novel treatment strategies. <bold>Methods</bold>Here, we identified l...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 38612804-9c5b-5040-a2c2-23787e770c90
DOI: 10.21203/rs.3.rs-810283/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Single-Cell RNA-seq Reveals LGALS1 and LAG3 as Novel Drivers of Ibrutinib Resistance in Chronic Lymphocytic LeukemiaDOI 10.21203/rs.3.rs-810283/v1Read

Single-cell Transcriptome Analysis Uncovers Heterogeneity and Key Regulators in Ibrutinib-resistant Chronic Lymphocytic LeukemiaSemantic proximity Read

Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.Semantic proximity Read

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapseSemantic proximity Read

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemiaSemantic proximity Read

Emerging Therapies in CLL in the Era of Precision MedicineSemantic proximity Read

LC-FACSeq is a method for detecting rare clones in leukemia.Semantic proximity Read

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinibSemantic proximity Read

Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Semantic proximity Read

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLLSemantic proximity Read